TRANSMEDICS GROUP

TransMedics unveiled a comprehensive growth plan that includes an OCS kidney program, expansion of national logistics, a push into Europe and the rollout of OCS 3.0. For 2026 the company expects revenue of $737–757 million and adjusted operating margins of 12.5–14%, with higher investments set to weigh on margins in the short term. Management is targeting long-term operating margins of around 30% by 2028 and sees the kidney program as potentially its largest development project, which could open access to up to roughly 30,000 additional procedures per year. TransMedics reported solid liquidity (more than $472 million) and emphasized that the business model would remain viable even without a possible OPO license. » Más en de.investing.com

TransMedics reported record second‑quarter revenue of about $190 million (+21% year‑over‑year) but missed analysts’ expectations with adjusted diluted earnings per share of $0.44 versus $0.5255 estimated. The logistics business grew strongly (+39% to $41 million) and the liver segment remained the largest revenue driver at $148 million. The company raised its full‑year revenue guidance but, citing higher investments, cut its outlook for the adjusted operating margin to 12.5–14%. Investors reacted negatively: the stock fell sharply intraday and in after‑hours trading. » Más en de.investing.com

Evercore ISI analyst Daniel Markowitz lowered TransMedics Group's price target to $90 from $100 while keeping an Outperform rating, citing stable procedure volumes and capital spending trends in the MedTech sector. Separately, TransMedics announced a strategic investment in PAD Aviation to expand its Organ Care System national program into Europe and build a pan‑European air and ground logistics network to boost organ transport and transplant access. » Más en finance.yahoo.com